Using conditioned place preference to identify relapse prevention medications.
about
Trace amine-associated receptor 1: A promising target for the treatment of psychostimulant addictionPharmacotherapeutic agents in the treatment of methamphetamine dependence.Hippocampal and Insular Response to Smoking-Related Environments: Neuroimaging Evidence for Drug-Context Effects in Nicotine DependenceAcid-sensing ion channels contribute to synaptic transmission and inhibit cocaine-evoked plasticity.Effects of the trace amine-associated receptor 1 agonist RO5263397 on abuse-related effects of cocaine in rats.Inhibition of urokinase plasminogen activator "uPA" activity alters ethanol consumption and conditioned place preference in mice.Cue configuration effects in acquisition and extinction of a cocaine-induced place preferenceSex differences in drug addiction and response to exercise intervention: From human to animal studiesEthanol and cocaine: environmental place conditioning, stereotypy, and synergism in planarians.Stress-Induced Reinstatement of Nicotine Preference Requires Dynorphin/Kappa Opioid Activity in the Basolateral Amygdala.Targeting GABAB receptors for anti-abuse drug discovery.Exposure to methylphenidate during infancy and adolescence in non-human animals and sensitization to abuse of psychostimulants later in life: a systematic review.Dorsal-CA1 Hippocampal Neuronal Ensembles Encode Nicotine-Reward Contextual Associations.Morphine-Associated Contextual Cues Induce Structural Plasticity in Hippocampal CA1 Pyramidal Neurons.Locomotor sensitization to intermittent ketamine administration is associated with nucleus accumbens plasticity in male and female rats.The sigma-1 receptor as a regulator of dopamine neurotransmission: A potential therapeutic target for methamphetamine addiction.Flood-conditioned place aversion as a novel non-pharmacological aversive learning procedure in mice.
P2860
Q28080716-629B81C9-4C71-42DB-9A21-DCD2E005C1BEQ30235058-7127254F-43AA-4835-9684-E7DF976085F4Q30697166-E34622E4-8388-4414-9A68-10E491AA3DB0Q33969340-9C59A560-A196-45FE-8E55-F4982C9FE027Q34068926-8951BE53-2E6E-42AF-B3F9-A62AA340E1FEQ34229752-D2D432AB-A71F-43AD-9B24-515D140509A7Q34275983-D8A3C7CD-3AFF-4A49-BA7C-8935C39E9EE1Q34485446-B04B06F0-5FF4-4765-A413-681804FFDDBAQ35619877-9CFEC4BD-1ECE-4754-8087-A6B91553A425Q37270938-4955CA6C-373D-4A0D-BBF7-BCFC888BF1A1Q38246629-1F91BC69-F209-41BA-A61E-B118E1E28F13Q38656883-4793C651-49DF-4295-8CEB-69CE5BA730F1Q41106578-A4275B11-5A77-4B7C-A428-352886931BC6Q41654835-42ECFA84-3FE6-4C9C-9B13-9116D452895BQ47299450-8E94D3F8-FB65-42A6-AB90-1E585B81D072Q47845016-31B26409-EFB5-43F7-A4F9-B4FA4FAE14EBQ55233976-898274E4-9783-4AEF-82F5-419A259A6EB4
P2860
Using conditioned place preference to identify relapse prevention medications.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Using conditioned place preference to identify relapse prevention medications.
@en
type
label
Using conditioned place preference to identify relapse prevention medications.
@en
prefLabel
Using conditioned place preference to identify relapse prevention medications.
@en
P2860
P1476
Using conditioned place preference to identify relapse prevention medications.
@en
P2093
Amy A Herrold
T Celeste Napier
P2860
P304
P356
10.1016/J.NEUBIOREV.2013.05.002
P433
P577
2013-05-13T00:00:00Z